Innovative ADCC and ADCP Technologies and Services for Cell Therapies and Therapeutic Antibodies
In this webinar, you will learn about:
- Implementing the HiBiT Target Cell Killing platform for a sensitive, specific, and consistent read-out of effector cell function
- Measuring ADCC and ADCP using HiBiT TCK Bioassays
- Evaluating Fc-mediated antibody functions for early discovery programs
Summary
The rising demand for cell therapies and therapeutic antibodies calls for innovative development technologies. A major challenge is the analysis of antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP), critical for therapeutic antibodies' effectiveness. Traditional ADCC and ADCP methods, dependent on primary cells, are laborious and highly variable, impeding drug development. Furthermore, accurately demonstrating target cell killing (TCK), a key mechanism for immunotherapy drugs, is difficult with conventional assays that cannot differentiate between target and effector cell deaths. These assays often require complex, labor-intensive processes and specialized equipment. Join our featured speakers, Julia Gilden from Promega and David Coberta Lopez from Charles River, as they highlight technological advances and share Charles River’s experiences with innovative bioassays. Discover how these solutions advance the development of cell therapies and therapeutic antibodies, making the discovery and manufacture of novel drugs more efficient and effective.
Speakers
Julia Gilden, PhD
Senior Research Scientist
Promega
Julia Gilden is a Senior Scientist at Promega Corp. Her group specializes in the development of bioassays for immuno-oncology applications, with a special focus on cell therapies and the use of primary human cells. She received her PhD in Biomedical Sciences with a focus in immunology from University of California, San Francisco and completed postdoctoral training in cell biology and parasitology at the University of Wisconsin Madison.
David Cobeta Lopez, MSc
Scientist
Charles River Laboratories
Leiden, The Netherlands
David Cobeta is a Scientist at Charles River Laboratories in Leiden, the Netherlands. His research revolves arounds early-stage research and discovery programs for novel drug therapies such as cell therapies and therapeutic antibodies focusing on evaluating their safety and efficacy profiles in vitro.